FB-102 is under clinical development by Forte Biosciences and currently in Phase I for Graft Versus Host Disease (GVHD). According to GlobalData, Phase I drugs for Graft Versus Host Disease (GVHD) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FB-102 overview
Forte Biosciences overview
Forte Biosciences is a biopharmaceutical company that focuses on autoimmune diseases. Its lead product candidate include FB-102 which is used for the for the treatment of autoimmune diseases such as graft-versus-host disease (GvHD), Vitiligo and Alopecia Areata (AA). GvHD is a complication associated with allogeneic hematopoietic stem cell transplantation. Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color. Alopecia Areata is patches of hair loss occur on the scalp or the body. The Company’s FB-102 program address key pathways in indications with a CD122 antagonist. Forte Biosciences is headquartered in Torrance, California, the US.
For a complete picture of FB-102’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
